Amchart Key Information
|Soft cap||15,000,000 USD|
|Hard cap||100,000,000 USD|
|Distributed in ICO||95%|
|Tokens for sale||115,000,000|
|Accepting||ETH, BTC, NEO, LTC|
|Price in ICO||1.0000 USD|
|Whitepaper||Click Here For View Whitepaper|
|Website||Click Here For Visit ICO Homepage|
The Game Change Team Behind Amchart
Current healthcare data problem
Pharma, life science, and research organizations have access to limited data, and what they do have access to comes from the United States and European markets. Amchart is a limiting factor for the creation of new drugs and interventions. What global healthcare data is available, typically resides either on paper (difficult to obtain), or EMR data which is antiquated and difficult to query. Imagine the ability to find, curate, and bring to market longitudinal healthcare data from pheno-types which are under represented in the marketplace, such as SE Asian, Latin American, and beyond.
The Amchart platform was created to bring these datasets to market, but more importantly, help provide physicians/organizations with the ability to use simple technologies to treat patients through EMR, patients to have ownership of their data through the Personal Health Record (PHR), and through collaboration between patients and providers through the Amchart Health Companion, the mobile app. In addition, they are creating a suite of analytic products, which in time, will be able to provide Clinical Decision Support (CDS) within the EMR to the provider and patients will begin to learn more about their health and well-being with recommendations within the PHR.
Asian market beginning with India
- 1.2 Billion people, which accounts for 25% of the world population
- High incidence of Chronic Disease
- 6X more likely to have Type 2 diabetes before age 50
- 3X more likely to have cardiovascular disease
- Largest growing ethnic group in the US
- Require specific treatment regimens that can follow the patient in India and abroad
Beyond For this Technology
The Amchart team realizes that technology can be a major hurdle to entry and it can be the difference between having digital records or staying on paper. So here is promise: they will gladly give the AmChart platform to you or your organization FOR FREE in exchange to work with you understanding your healthcare data, helping patients be empowered with their data, and to help pharma and life science companies work with this data to enact helpful interventions!
What about the United states market?
Amchart haven’t forgotten about roots…your goal is not the EMR market, but rather how to use pieces of the AmChart ecosystem within the United States. They will be targeting insurance companies who want to use your Health Companion for vital sign management, Health Information Exchanges (HIEs) who want to utilize analytics and PHR as a patient portal, and provider organizations who want to engage their patients in specific healthcare initiatives.